Literature DB >> 15797572

Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.

Mohamed S Rashed1, Lujane Y Al-Ahaidib, Osama Y Al-Dirbashi, Mohammad Al Amoudi, Moeen M A Al-Sayed, Zuhair Rahbeeni, Zuhair Al-Hassnan, Abeer Al-Dbaas, Mohamed Al-Owain, Michelle Ni Luanaigh.   

Abstract

We describe an isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of succinylacetone (SA) in urine for the diagnosis of hepatorenal tyrosinemia (HT1). The method used 15N-labeled 5(3)-methyl-3(5)-isoxazole propionic acid as internal standard. Urine samples were oximated with hydroxylamine hydrochloride at 80 degrees C, extracted by solvent-solvent extraction, and followed by derivatization of the butyl ester. The butylated isoxazole derivatives of SA and its internal standard were detected and quantified using positive ion electrospray LC-MS/MS with selected reaction monitoring. The turnaround time between injections was 10 min. Calibration curves were linear over the range of 0.0633-63.3 micromol/L. The intra- and interday assay variations were less than 7%. Mean recoveries of SA at three different concentrations ranged from 96 to 109%. During the course of this study, we identified 12 new patients with HT1 and applied this method to follow up the treatment of 4 of these patients as well as previously diagnosed HT1 patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797572     DOI: 10.1016/j.ab.2005.01.014

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  4 in total

1.  Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.

Authors:  Jan-Ulrich Schlump; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  Eur J Pediatr       Date:  2009-10-08       Impact factor: 3.183

Review 2.  Emerging trends in paper spray mass spectrometry: Microsampling, storage, direct analysis, and applications.

Authors:  Benjamin S Frey; Deidre E Damon; Abraham K Badu-Tawiah
Journal:  Mass Spectrom Rev       Date:  2019-09-06       Impact factor: 10.946

3.  Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007).

Authors:  D Matern; S Tortorelli; D Oglesbee; D Gavrilov; P Rinaldo
Journal:  J Inherit Metab Dis       Date:  2007-07-23       Impact factor: 4.982

4.  Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.

Authors:  Sarar Mohamed; Mohammed A Kambal; Nasir A Al Jurayyan; Abdulrahman Al-Nemri; Amir Babiker; Rana Hasanato; Abdullah S Al-Jarallah
Journal:  BMC Res Notes       Date:  2013-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.